Skip to main content
. 2017 Feb 14;37(4):1989–1997. doi: 10.3892/or.2017.5443

Figure 3.

Figure 3.

XWLC05 ERCC1-shRNA cell line and its control xenograft tumor burden in mice with or without the treatment of cisplatin. (A and B) In vivo tumorigenesis examined by animal assay and subcutaneous tumor growth from mice injected with XWLC05 ERCC1-shRNA cell line and its control with or without the treatment of cisplatin (n=7 for each group, P<0.05 in XWLC05 ERCC1-shRNA groups). Error bars 95% CIs. Images show tumor volume and tumor weight of mice at the end of observation. (C) Immunohistochemical staining of xenograft tumor tissues. Tissues were stained with rabbit anti-ERCC1 antibody and visualized with goat anti-rabbit secondary antibody (magnification of ×400).